Prostate cancer pathology audits: Is central pathology review still warranted?

Canadian Journal of Urology

Volumn 19, Issue 3, 2012, Pages 6256-6260

  D'Souza, Neil ^a   Andrew Loblaw, D ^a   Mamedov, Alexandre ^a   Sugar, Linda ^a   Holden, Lori ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Central pathology review; Gleason grading; prostate cancer; Quality assurance

Indexed keywords

ARTICLE; CANCER GRADING; CLINICAL COMPETENCE; HUMAN; MALE; MEDICAL AUDIT; NEEDLE BIOPSY; OBSERVER VARIATION; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; RETROSPECTIVE STUDY;

BIOPSY, NEEDLE; CLINICAL AUDIT; CLINICAL COMPETENCE; HUMANS; MALE; NEOPLASM GRADING; OBSERVER VARIATION; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 84871886781     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Canadian Cancer Society. Prostate Cancer Stats. http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20 statistics/Stats%20at%20a%20glance/Prostate%20cancer. aspx?sc_lang=en. Last accessed November 8, 2010.
2. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507.
3. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23(28):7005-7012.
4. Walz J, Chun FK, Klein EA et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 2009;181(2):601-607.
5. Fine SW, Epstein JI. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol 2008;179(4):1335-1338.
6. King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer 2000;90(6):305-311.
7. Lattouf JB, Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002;90(7):694-698.
8. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152(5 Pt 2):1826-1830.
9. San Francisco IF, DeWolf WC, Rosen S et al. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 2003;169(1):136-140.
10. Steinberg DM, Sauvageot J, Piantadosi S et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21(5): 566-576.
11. Cancer Care Ontario. Pathology Reporting Project Information for Professionals. http://www.cancercare.on.ca/cms/One.aspx? portalId=1377&pageId=48158. Last accessed November 11, 2010.
12. Rubin M, Bismar T, Curtis S, Montie J. Prostate needle biopsy reporting: how are the surgical members of urologic oncology using pathology reports to guide treatment of prostate cancer patients? Am J Surg Pathl 2004;28(7):946-952.
13. Burchardt M, Engers R, Muller M, Burchart T et al. Interobserver reproducibility on Gleason grading: evaluation using prostate cancer tissue microarrays. J Cancer Res Clin Oncol 2008;134(10): 1071-1078.
14. Bova GS, Parmigiani G, Epstein JI, Wheeler T, Mucci NR, Rubin MA. Web-based tissue microarray image data analysis: initial validation testing through prostate cancer Gleason grading. Hum Pathol 2001;32(4):417-427.
15. Chen RC, Clark JA, Talcott JA. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009;27(24):3916-3922.
16. Pickles T, Keyes M, Morris WJ. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis. Int J Radiat Oncol Biol Phys 2010;76(1): 43-49.
17. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8(4):1314-1322.
18. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Clin Oncol 2008;180(4):1438-1443.
19. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448-4456.
20. Alibhai SMH, Duong-Hua M, Sutradhar R et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27(21):3452-3458.
21. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol 2007; 25(34): 5359-5365.
22. Love AW, Scealy M, Bloch S et al. Psychosocial adjustment in newly diagnosed prostate cancer. Aust N Z J Psychiatry 2008;42(5): 423-429.
23. Rosenfeld B, Roth AJ, Gandhi S et al. Differences in health related quality of life of prostate cancer patients based on stage of cancer. Psychooncology 2004;13(11):800-807.
24. Bellizzi KM, Latini DM, Cowan JE et al. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology 2008;72(6):1269-1273.
25. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-1261.
26. Burnett AL, Aus G, Canby-Hagino ED et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 2007;178(2):597-601.
27. Hinz A, Krauss O, Stolzenburg JU et al. Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study. Urol Oncol 2009;27(4):367-372.
28. Bacon CG, Giovannucci E, Testa M et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002;94(3):862-871.
29. Hu J, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. J Urol 2003;169(6):2279-2283.
30. Clark JA, Inui TS, Silliman RA et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 2003;21(20):3777-3784.
31. Diefenbach MA, Mohamed NE. Regret of treatment decisions and its association with disease-specific quality of life following prostate cancer treatment. Cancer Invest 2007;25(6):449-457.
32. Epstein JI, Allsbrook WC Jr, Amin MB et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathl 2005;29(9): 1228-1242.
33. Brimo F, Schultz L, Epstein JI. The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 2010;184(1):126-130.
34. Kuroiwa K, Shiraishi, Ogawa O, Usami M. Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol 2010;183(3):952-957.
35. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23(3):273-279.
36. Ozdamar SO, Sarikaya S, Yildiz L, Atilla MK, Kandemir B, Yildiz S. Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas. Int Urol Nephrol 1996;28(1):73-77.
37. Cintra ML, Billis A. Histologic grading of prostatic adenocarcinoma: intraobserver reproducibility of the Mostofi, Gleason and Bocking grading systems. Int Urol Nephrol 1991;23(5): 449-454.
38. Rakovitch E, Mihai A, Pignol JP et al. Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ? Breast Cancer Res Treat 2004;87(3):265-272.
39. Verkooijen HM, Peterse JL, Schipper MEI et al. Interobserver variability between general and expert pathologists during the histological assessment of large-core needle and open biopsies of non-palpable breast lesions. Eur J Cancer 2003;39(15):2187-2191